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Abstract
Circadian clocks coordinate the timing of important biological processes. Interconnected transcriptional and post-
translational feedback loops based on a set of clock genes generate and maintain these rhythms with a period of about
24 hours. Many clock proteins undergo circadian cycles of post-translational modifications. Among these modifications,
protein phosphorylation plays an important role in regulating activity, stability and intracellular localization of clock
components. Several protein kinases were characterized as regulators of the circadian clock. However, the function of
protein phosphatases, which balance phosphorylation events, in the mammalian clock mechanism is less well understood.
Here, we identify protein phosphatase 1 (PP1) as regulator of period and light-induced resetting of the mammalian circadian
clock. Down-regulation of PP1 activity in cells by RNA interference and in vivo by expression of a specific inhibitor in the
brain of mice tended to lengthen circadian period. Moreover, reduction of PP1 activity in the brain altered light-mediated
clock resetting behavior in mice, enhancing the phase shifts in either direction. At the molecular level, diminished PP1
activity increased nuclear accumulation of the clock component PER2 in neurons. Hence, PP1, may reduce PER2
phosphorylation thereby influencing nuclear localization of this protein. This may at least partially influence period and
phase shifting properties of the mammalian circadian clock.
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Introduction
Many behavioral, physiological and metabolic functions are
temporally organized and show daily rhythms, even in the absence
of external timing cues. Temporal coordination of biological
processes separates biochemically incompatible reactions, opti-
mizes an organism’s energy expenditure, and may improve overall
performance. Circadian (=‘about a day’) oscillations are based on
an autonomous clock mechanism that is phase-controlled and
synchronized with the environment by external time cues, such as
light or food. In mammals, the central circadian pacemaker is
located in the suprachiasmatic nucleus (SCN), a structure in the
ventral hypothalamus. Light, which serves as strong timing cue or
Zeitgeber, directly impinges on the cellular oscillators of SCN
neurons via the retinohypothalamic tract. The SCN can integrate
this temporal information and coordinate all body clocks to
establish and maintain adequate phase-relationships between
different tissue clocks (reviewed in [1]).
The cell-autonomous clockwork that generates circadian
oscillations is composed of interlocked transcriptional-posttransla-
tional feedback loops [2]. These loops control the rhythmic
expression of transcriptional activators and repressors whose
interplay generates rhythms of approximately 24 hours. In the
essential core feedback loop of the mammalian clock, two
transcriptional activators, BMAL1 [3,4] and CLOCK (or NPAS2
in the brain) [5,6,7], drive the expression of the Period (Per1-3) [8,9]
and Cryptochrome (Cry1-2) [10] genes via binding to E-boxes on the
promoters of these genes. PER and CRY proteins form complexes
and re-enter the nucleus, where they inhibit their own transcrip-
tion [11,12,13]. This core loop can directly be influenced by
environmental resetting signals via cAMP response element
binding protein (CREB)-mediated induction of Per gene expression
[14,15]. This induction of the Per genes is involved in the light-
mediated readjustment of the mammalian circadian oscillator to
environmental time [16,17,18,19].
Post-translational modifications of several clock components are
required to adjust the period length of the feedback loops to
24 hours and to allow proper phase adjustments of the clock.
Among these modifications, protein phosphorylation plays a
critical role. Most clock proteins can be phosphorylated at
multiple sites to determine their stability, activity and subcellular
localization (reviewed in [20,21]). The clock component PER2
appears to be highly regulated by phosphorylation. PER2 has at
least 21 phosphorylated residues [22] and several kinases were
described as regulators of PER2 [23,24,25]. A mutation found in
the human Per2 gene causes familial advanced sleep phase
syndrome (FASPS) [26]. Interestingly, mutation of the FASPS
site (S662) of an hPER2 transgene affects the period of the
circadian oscillator in mice in opposite directions depending on
whether the mutation mimics hypo- or hyperphosphorylation [27].
This suggests that the balance of protein kinase and phosphatase
activity that controls the net phosphorylation state of every
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functioning. Protein serine/threonine phosphatases have been
implicated in the regulation of circadian rhythms in dinoflagellates
[28], neurospora [29] and the fruit fly [30,31]. In mammals,
phosphatases were shown to affect the expression of the clock
component PER2 in cell culture [32,33], indicating evolutionary
conserved mechanisms. However, their precise function in the
mammalian circadian mechanism has not been investigated in vivo.
Here, we examined the impact of protein phosphatase 1 (PP1)
on circadian rhythmicity and photic entrainment of the mamma-
lian circadian clock. PP1 is one of the major and most abundant
eukaryotic protein serine/threonine phosphatases and has been
implicated in various biological processes such as cell division,
metabolism, synaptic plasticity, transcription and translation
(reviewed in [34]). Activity, substrate specificity and intracellular
localization of this enzyme are tightly regulated by the interaction
with over 50 established or putative targeting and regulatory
subunits [34,35]. To study the function of PP1, PP1 activity was
modulated in cells and in the brain of transgenic mice by inducible
expression of the regulatory protein inhibitor-1 (I-1) or Nuclear
Inhibitor of PP1 (NIPP1). Our results indicate that PP1 influences
the period length of the mammalian circadian oscillator and is
involved in mediating the response of the oscillator to entraining
light information. At the cellular level, PP1 appears to be
implicated in the regulation of the subcellular localization of the
PER2 protein. Hence, PP1 is an important opponent of kinases
within the mammalian circadian clock.
Results
Protein phosphatase 1 (PP1) influences circadian period
length in vitro
To get insights in the function of PP1 in the mammalian clock
mechanism, we reduced the expression of various catalytic
subunits of PP1 in human osteosarcoma U-2 OS cells by RNA
interference. These cells contain a Bmal1 promoter luciferase
reporter that is stably integrated into the genome allowing the
monitoring of circadian rhythms in vitro [24]. In mammals, three
genes encode the PP1 catalytic subunits PPP1CA, PPP1CB, and
PPP1CC [34]. These subunits are ubiquitously expressed and are
targeted to varying but distinct intracellular locations by the
interaction with regulatory proteins. The expression of PPP1CA,
PPP1CB or PPP1CC was reduced by lentiviral infection of U-2
OS reporter cells with RNAi constructs specific for the respective
subunits with more than 75% knock-down efficiency at the mRNA
level (Figure S1A). Cells were synchronized with dexamethasone
and the rhythmic bioluminescence was continuously monitored for
several days. As a result, knock-down of PPP1CA, PPP1CB or
PPP1CC provoked lengthening of the circadian period of U-2 OS
cells of up to two hours (Figure 1A, 1B, S1B).
In a second approach we wanted to interfere with PP1 activity
in a biochemical manner. We used NIH 3T3 mouse fibroblasts
that express a constitutively active form of inhibitor-1 (I-1), an
endogenous inhibitor of PP1 [36]. The constitutively active form
corresponds to a short form of I-1 (amino acids 9 to 54), in which
the threonine residue that is normally phosphorylated by protein
kinase A is substituted by a phosphomimicking aspartic acid
residue [37]. This constitutively active form of I-1 is designated
I-1*. NIH 3T3 cells were transfected with a Bmal1 luciferase
reporter together with either empty expression vector or increas-
ing amounts of an expression vector for HA-tagged I-1*. Similar to
the knock-down experiments, the expression of HA-I-1* length-
ened the period of the Bmal1 luc oscillations (Figure 1C). This
lengthening was dose-dependent for two concentrations of
HA-I-1* expression vector (0.1 mg and 0.2 mg) and appeared to
reach saturation at a concentration of 0.4 mg (Figure 1D). I-1*
expression led to periods that were up to 50 minutes longer than
the period of control cells. Altogether, these results indicate that
PP1 is involved in the determination of the circadian period length
in mammalian cells.
I-1* mutant mice tend to have a longer free-running
period
To assess the importance of PP1 on circadian behavior, PP1
activity was reversibly reduced specifically in the brain of
transgenic mice (and not in other tissues). Mutant mice expressed
inducibly the constitutively active form of inhibitor 1 (I-1*) [38].
Expression of I-1* was regulated by a tetracycline-controlled
transactivator (rtTA2 transgene) system under the control of the
Ca
2+/calmodulin-dependent protein kinase alpha (CaMKIIalpha)
promoter [39] that is also active in the SCN [40]. Double
transgenic mice (I-1* mutant mice; rtTA2
+/I-1*
+) were treated
with doxycycline in order to induce I-1* mRNA expression in the
forebrain and hence leading to a reduction of PP1 activity. Control
mice were animals having either one of the transgenes or no
transgene (rtTA2
2/I-1*
2; rtTA2
2/I-1*
+; rtTA2
+/I-1*
2). They
underwent the same treatment as indicated for double transgenic
mice.
We analyzed the wheel running locomotor activity before the
doxycycline treatment (off dox), during the doxycycline treatment
(on dox) and after the doxycycline treatment (on/off dox). Control
and I-1* mutant mice entrained similarly to a 12-h light/12-h
darkness cycle (LD 12:12 h cycle) under on dox conditions
(Figure 2A, 2B) and displayed stable free-running activity rhythms
when maintained in constant darkness (DD; Figure 2A, 2B).
Similar to the lengthening of the period in cells expressing I-1*,
I-1* expression in the brain appears to provoke a longer free-
running period compared to control mice (Figure 2C, on dox).
This phenotype was not present under uninduced conditions
(mutant off dox). Of note is the fact that doxycycline appears to
shorten the period length in all genotypes as revealed by repeated
measures 2-way ANOVA and paired t-test analysis (Table S2).
The genotype as well as the treatment affected the results
(F=17.73, DFn=1, DFd=42, p=0.0004; F=32.74, DFn=2,
DFd=42, p,0.0001, respectively) and the matching was effective
(F=2.65, DFn=21, DFd=42, p=0.0035). However, interaction
between genotype and treatment appears to be significant
(F=3.79, DFn=2, DFd=42, p=0.03) indicating that the p
values are difficult to interpret since the shortening effect of
doxycycline is different depending on the genotype. In contrast to
cells expressing I-1*, we observed only a trend towards a longer
period in mice expressing I-1*. This is probably due to a less
efficient reduction of PP1 activity in our mice compared to the
knock-down in cells. To confirm I-1* expression and consequent
reduction of PP1 activity in the SCN, we measured PP1 activity in
the SCN of control and I-1* mutant mice under on dox
conditions. PP1 activity was significantly reduced by 20% in I-1*
mutant mice compared to control animals (Figure 2D).
Protein phosphatase 1 is involved in light-induced clock
resetting
In addition to the importance of phosphorylation events for
steady state oscillator functions, protein phosphorylation is an
important mediator of light-induced resetting of the clock (for
review see [41]). Thus, we analyzed the ability of I-1* mutant mice
to reset the clock in response to light presented during the
subjective night. We performed light pulses using an Aschoff type I
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(off dox and on/off dox). Animals were maintained in constant
darkness and 15-min light pulses of 400 lx were administered. The
light pulses corresponded to a pulse at circadian time (CT) 10
which is during the subjective day and should not have an effect on
the oscillator, and light pulses at CT14 and CT22, which should
provoke a phase delay and phase advance of the oscillator,
respectively. Both, control and I-1* mutant mice, did not phase
shift their locomotor behavior in response to light presented at
CT10 under uninduced or induced conditions (Figure 3A).
Figure 1. Reduction of PP1 activity increases period length in vitro. (A) Representative real-time bioluminescence records of U-2 OS cells
harboring a Bmal1 luciferase reporter vector that were lentivirally transduced with a construct containing scrambled RNAi (non-silencing control) or
RNAi constructs against the catalytic subunits of PP1 (PPP1CA, PPP1CB, and PPP1CC; representative experiment out of three independent
experiments; mean of three cultures). (B) Average period length of Bmal1 luc oscillations in U-2 OS cells lentivirally transduced with RNAi constructs
against the catalytic subunits of PP1. Period length was determined in three independent experiments (with n=2–3 cultures). (C) NIH 3T3 cells were
transfected with a Bmal1 luciferase reporter vector together with either the empty expression vector or an expression vector for I-1* (0.2 mg). Cells
were synchronized with dexamethasone, and luciferase activity was measured in real-time using a LumiCycle apparatus. Luciferase counts are plotted
as mean of 3 cultures (representative experiment out of four independent experiments). (D) Average period length of Bmal1 oscillations of
transfected NIH 3T3 cells. Cells were transfected with 1.5 mg luciferase reporter vector, 0.1 mg pCMV-SEAP and 0.1 mg, 0.2 mg or 0.4 mg of empty
expression vector/HA-I-1* expression vector (n=13 individual cultures). *** p,0.001, * p,0.05 indicating significance (1-way Anova).
doi:10.1371/journal.pone.0021325.g001
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mice displayed phase delays of 2148.865.5 min (mean 6 SEM)
that were approximately 40 min greater than the phase delays of
control animals (2107.965.5 min; Figure 3B). This phenotype
was due to I-1* expression and reduction of PP1 activity as it was
fully reversed by suppressing transgene expression (on/off dox
condition; Figure 3B). Similar to the more pronounced phase
delays, I-1* mutant mice also showed larger phase advances
compared to control mice after a light pulse presented at late
subjective night (CT22; 78.4668.4 min for I-1* mutant and
38.3464.45 for controls, respectively; Figure 3C). Again, phase
advances were similar in control and I-1* mutant mice before
doxycycline induction (off dox) or when transgene expression was
suppressed (on/off dox) indicating that PP1 activity is involved in
the observed resetting phenotypes.
The action of PP1 in determining the period length of the
mammalian clock and in modulating the response of the oscillator
towards light may be via dephosphorylation events in the
cytoplasm, in the nucleus, or both. To investigate the role of
PP1 specifically in the nucleus, we measured circadian parameters
in mice expressing a fragment of the Nuclear Inhibitor of PP1
(NIPP1). This fragment contains the PP1 inhibition domain and
the nuclear localization domain of NIPP1 and is constitutively
active in the nucleus of cells (NIPP1*; [43]). NIPP1* was expressed
in an inducible manner using the doxycycline-dependent rtTA2
and the CaMKIIalpha promoter in a similar manner as in the I-1*
animals. NIPP1* mice had robust free-running rhythms in DD
(Figure S2A, S2B) with a trend towards a slightly longer period
under on dox conditions (Figure S2C). Similar to I-1* mutant
mice, NIPP1* mutants showed significantly larger phase delays
(Figure 3D, on dox) and phase advances (Figure 3E, on dox) after
light pulses at CT14 and CT22, and this could be fully reversed
after dox treatment (Figure 3D, 3E, on/off dox).
Altogether, these results suggest that PP1 is involved in the
mechanism that mediates resetting of the clock in the brain in
response to the Zeitgeber light. Our results further indicate
Figure 2. Dox-dependent and reversible lengthening of the circadian period of I-1* mutant animals. (A, B) Representative locomotor
activity records of control (A) and I-1* mutant mice (B) under doxycycline treatment. Wheel-running activity is shown under free-running conditions
in constant darkness (DD). (C) Average period length of control and I-1* mutant mice as determined by x
2-periodogram analysis under off dox, on
dox and on/off dox conditions. Data are represented as mean 6 SEM: control (off dox 23.8860.03 h, n=14; on dox 23.4560.06 h, n=14; on/off dox
23.6560.05 h, n=14), I-1* mutant (off dox 23.9860.03 h, n=9; on dox 23.7660.05 h, n=9; on/off dox 23.9060.03 h, n=9); ** p,0.01, * p,0.05
indicating significance (2-way Anova with Bonferroni post-test). (D) PP1 activity (% total activity) was measured in extracts from SCN tissue in control
and I-1* mutant mice under doxycycline treatment. PP1 activity of control animals was set to 100% and mutant values were calculated in relation.
Represented is the mean 6 SEM (n=8, ** p,0.01 indicating significance (unpaired t-test)).
doi:10.1371/journal.pone.0021325.g002
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21325Figure 3. Light-induced resetting is altered in I-1* and NIPP1* mutant mice. (A–C) Shown are representative locomotor activity records
before and after a 15-min light pulse of control (left panels) and I-1* mutant mice (middle panels) under on dox conditions. Red asterisks indicate the
timing of the light pulse. The light pulse was administered at CT10 (A) (off dox n=8 control, n=3 mutant; on dox n=20 control, n=12 mutant; on/off
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activity.
PP1 affects PER1 and PER2 accumulation
Light-induced resetting of the circadian clock involves activation
of several signaling cascades and phospho-CREB mediated
induction of the Per genes in the SCN [14,15,44,45]. This light-
dependent induction of the Per genes (Per1 and Per2) is suggested to
affect the circadian oscillator in the SCN in response to light and
consequently to phase-adjust the oscillator [46].
To test whether PP1 impinges on Per gene induction, we
measured light-mediated Per1 and Per2 induction in the SCN in
control and I-1* mutant mice at the beginning or the end of the
subjective night. Interestingly, we observed a similar induction of
Per1 and Per2 one hour after a light pulse at CT14 (Figure S3A,
S3B) or CT22 (Figure S3C, S3D) in both I-1* and control mice.
Quantifications and representative micrographs do not reveal any
differences in the magnitude or localization of gene induction
within the SCN between control and mutant mice. Thus, PP1
activity in the brain is probably less important for the induction of
Per expression in the SCN in response to light. Consequently, PP1
may act on the phase shifting capacity of the circadian oscillator
via another, maybe post-transcriptional mechanism.
A previous study suggests that PP1 targets the clock component
PER2 in vitro [33]. To test whether modulating PP1 activity affects
clock protein expression or localization in vivo, we analyzed the
clock proteins in nuclear extracts prepared from coronal brain
slices containing the SCN or from liver tissue (as not I-1*
expressing tissue). Control animals and I-1* mutant mice
maintained in a LD 12:12 h cycle under on dox conditions were
sacrificed every six hours. We observed altered accumulation
patterns of PER1 and PER2 in brain nuclear extracts from I-1*
mutant mice compared to nuclear extracts from control animals
(Figure 4A). I-1* mutant animals displayed higher levels of nuclear
PER1 and PER2 at ZT2 and ZT20. To a lower extent this
appears also to be the case for BMAL1. By contrast, CLOCK
nuclear accumulation was similar in both, extracts from control
and I-1* mutant mice. Moreover, expression patterns of PER1,
PER2, BMAL1 and CLOCK were comparable in liver extracts
from the same animals (Figure 4B) indicating that the observed
effect was due to the brain-specific expression of I-1*.
Altered PER protein accumulation observed in brain nuclear
extracts might be due to changes in the overall amount of PER
proteins or changes in their intracellular localization. To get
insights on this, we analyzed PER2 expression in the SCN of I-1*
mice by immunohistochemistry. Immunohistochemical stainings
comparing the expression of PER2 in the SCN of control and I-1*
mice revealed PER2 to be rhythmically expressed in the SCN of
both genotypes, with the higher amount of antiPER2-immunore-
active nuclei present at ZT14 and ZT20 (Figure S4A). No
apparent differences regarding phase and magnitude of PER2
expression were found between control and I-1* mutant mice
under induced conditions. However, the analysis of immunohis-
tochemical stainings at ZT2 at a higher magnification indicated
slight differences in the subcellular distribution of the antiPER2
signal in control and mutant animals (Figure S4B). In SCN
sections from I-1* mutant mice, elevated levels of nuclear PER2
were detected compared to control animals (62.6% in I-1* mutant
animals and 48.9% in control animals, Figure S4C).
I-1* expression alters the subcellular localization of PER2
in vitro
In order to confirm our observations in SCN tissue we
investigated the effects of I-1* expression on the localization of
the PER2 protein in cultured cells. To this end we analyzed the
expression and subcellular localization of a GFP-tagged version of
PER2 in NG108-15 neuroblastoma cells, since this cell line is of
neuronal and glial origin. GFP-PER2 was expressed either with
empty expression vector or expression vectors for I-1* or CRY1.
In NG 108-15 cells, exogenously expressed PER2-GFP was found
predominantly in the cytoplasm, although some cells expressed
PER2-GFP also in the nucleus (Figure 5A, 5B). Co-expression of
the clock component CRY1 promoted nuclear localization of the
PER2 protein (3.4%66.2 nuclear localization in control cells
versus 83.5%611.4 in CRY1-expressing cells; p,0.001; Figure 5).
This is in agreement with previous studies [13,47]. Compared to
control cells, significantly more PER2 localized to the nucleus
when I-1* was co-expressed with PER2-GFP in NG 108-15 cells
(3.4%66.2 nuclear localization in control cells versus 16.0%69.5
in HA-I-1*-expressing cells; p,0.01; Figure 5). Both the fraction of
cells expressing PER2-GFP in the nucleus, and in nucleus/
cytoplasm increased (Figure 5B). The same tendency was
observed, when NIPP1* was co-expressed with PER2 (Figure
S5A, S5B). The nuclear accumulation of PER2 was not due to a
general effect of the inhibitor expression on GFP localization, as
the subcellular localization of GFP-tagged beta-Catenin was not
influenced in these cells (Figure S5C).
In conclusion it appears that I-1* expression and thereby PP1
inhibition in the brain does not have a major effect on the total
amount of PER2 in neurons. However, our experiments indicate
that PP1 may be involved in the regulation of the subcellular
localization of the PER2 protein.
Discussion
Post-translational modifications of clock components such as
ubiquitination, acetylation and phosphorylation have critical
functions in the mammalian circadian clock [21]. A basic
transcriptional-translational feedback loop alone would operate
only in a range of a few hours [48]. Post-translational regulation is
an elegant way to add delays of several hours between activation
and repression of transcription and consequently to adjust the
period of the circadian clock to the 24-hour day. By regulating
clock protein stability, activity, and/or subcellular localization,
protein phosphorylation plays a crucial role in the maintenance of
the 24-hour rhythm. Several clock components are subject to
phosphorylation (reviewed in [21]). Among the mammalian clock
proteins, phosphorylation of the PER proteins appears to have a
special importance for the dynamics of the circadian cycle.
Kinases of the casein kinase (CK) 1 and 2 family have been
shown to determine the period of the circadian system by targeting
dox n=8 control, n=3 mutant), CT14 (B) (off dox n=11 control, n=9 mutant; on dox n=21 control, n=15 mutant; on/off dox n=12 control, n=8
mutant) or CT22 (C) (off dox n=14 control, n=11 mutant; on dox n=19 control, n=13 mutant; on/off dox n=15 control, n=9 mutant). Red lines
represent the onset of activity before and blue lines the onset of activity after the light pulse, respectively. The quantification of the phase shifts
under off dox, on dox and on/off dox conditions is indicated in the right panels. (D–E) Light-induced phase shifts in control and NIPP1* mice after a
light pulse at CT14 (D) (off dox n=6 control, n=3 mutant; on dox n=9 control, n=8 mutant; on/off dox n=3 control, n=5 mutant) or CT22 (E) (off
dox n=6 control, n=3 mutant; on dox n=8 control, n=8 mutant; on/off dox n=3 control, n=5 mutant) under off dox, on dox, and on/off dox
conditions. Significant differences were determined by 1-way Anova; *** p,0.001; * p,0.05. Presented is the mean 6 SEM.
doi:10.1371/journal.pone.0021325.g003
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ylated residues in the PER proteins affect the period length of the
oscillator. The FASPS mutation of hPER2 (S662G) results in
PER2 being hypophosphorylated by CK1 in vitro [26]. Interest-
ingly, mice carrying this mutation display a shorter period length
in DD [27]. By contrast, the mutation of the FASPS site of hPER2
to a phosphomimicking aspartate residue leads to a significantly
longer period. This result highlights that phosphorylation events at
specific residues are dynamic but are highly balanced to maintain
circadian cycles of about 24 hours. Reversibility is achieved by the
interplay of protein kinases and phosphatases.
Studies in several organisms suggested functions of protein
serine/threonine phosphatases in regulating circadian rhythmicity
[28,29,30,31]. Therefore, we were interested to see, whether PP1
has important functions in the mammalian clock mechanism. We
provide evidence that this enzyme influences the dynamics of the
mammalian circadian timing system. Down-regulation of the
catalytic subunits of PP1 by RNAi and of PP1 activity by over-
expression of a constitutively active inhibitor I-1* lengthened the
period of luciferase rhythms in cells (Figure 1). Furthermore, mice
expressing constitutively active PP1 inhibitors in the brain
displayed behavioral rhythms with a longer period length
(Figure 2C) than control mice, suggesting a function of PP1 in
regulating the period of the circadian oscillator in vivo. This
phenotype is similar to the phenotype observed in fruit flies having
reduced PP1 activity [30]. Flies over-expressing NIPP1 in clock
neurons exhibited a significantly lengthened circadian period.
Interestingly, these flies also showed high amplitude light-induced
resetting. The same phenotype was observed in I-1* as well as
NIPP1* mutant mice (Figure 3). Hence, the role of PP1 in
controlling clock parameters may be evolutionarily conserved at
least between Drosophila and mammals.
PP1 is an ubiquitous protein serine/threonine phosphatase that
has been implicated in various biological processes [34]. By the
specific interaction of the PP1 catalytic subunits with various
regulatory and targeting proteins, activity and substrate specificity
are highly regulated. In a previous study, PP1 was shown to
coimmunoprecipitate with, dephosphorylate and stabilize the
PER2 protein in HEK293 cells [33]. In our study, we found only
a minor effect of PP1 on the stability of PER2 in the brain and of
overexpressed full-length PER2 in NG 108-15 neuroblastoma cells
(Figure S4A, 5, S6). In particular, expression of PP1 inhibitors
(HA-I-1* or HA-NIPP1*) did not affect the half-life of V5-tagged
full-length PER2 in NG 108-15 cells treated with cycloheximide
(Figure S6). This discrepancy may be due to tissue-specific
differences in PP1 action on PER2 that may involve different
regulatory components. However, comparing protein expression
patterns in brain nuclear extracts, we found differences in the
Figure 4. Protein expression in nuclear extracts from brain and liver. Nuclear extracts from coronal brain slices containing the SCN (A; pool
of two animals) and liver (B) from control and I-1* mutant mice under on dox conditions were prepared at 6-h intervals from mice held in a 12-h light/
12-h dark cycle (LD 12:12 h cycle). The protein accumulation patterns were analyzed by Western blot analysis using the indicated antibodies. The
accumulation of RNA polymerase II (antiPOL2) is shown as loading control. Below the quantification of PER2 levels in nuclear extracts from brain and
liver is shown (n=4 animals; t-test control vs. mutant at ZT2 and ZT20, p,0.05 for brain, p.0.05 for liver).
doi:10.1371/journal.pone.0021325.g004
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I-1* mutant mice (Figure 4). Moreover, a larger fraction of PER2-
GFP was located in the nucleus of neuroblastoma cells expressing
I-1* or NIPP1* compared to control cells (Figure 5, S5). From
these results, we conclude that PP1 influences the subcellular
localization of PER2 by tipping the PER2 cytoplasmic to nuclear
ratio towards the cytoplasmic fraction. Taken together, our and
previous studies suggest PER2 as a molecular target of PP1.
Timing of nuclear entry and the dynamics of nuclear accumula-
tion of the components of the repressor complexes containing
PER2 influence the period of the circadian oscillator [22,24].
Hence, we can speculate that PP1 impacts on the period partially
via the PER2 protein. However, a slight effect of PP1 inhibition
was observed for BMAL1, indicating that PP1 may not act on
PER protein accumulation only, but may also affect BMAL1 levels
possibly via epigenetic modifications on the transcriptional
machinery [43].
In addition to affecting oscillator function under constant
conditions, we show that PP1 is involved in the mechanisms in the
SCN that mediate the response of the oscillator to entraining light
input (Figure 3). Entrainment of the clock employs several signal
transduction cascades that depend on protein phosphorylation (for
review see [41]). A recent study shows that the pleckstrin
homology domain leucine-rich repeat protein phosphatase 1
(PHLPP1), which counteracts Akt, protein kinase C (PKC), and
ERK1/2 signaling, impacts on resetting by modifying the period
length after a light stimulus [51]. This further highlights the
importance of balanced activities between protein kinases and
Figure 5. Inhibition of PP1 in cells modulates PER2 subcellular localization. (A) NG108-15 cells were transfected with PER2-GFP together
with either empty expression vector (control, upper panels), expression vector for HA-tagged I-1* (HA-I-1*; middle panels), or CRY1 (lower panels).
Representative fluorescent microscopic images are shown. From left: EGFP fluorescence (green), Hoechst-stained nuclear fluorescence (blue) and a
merge of these images. Scale bar: 20 mm. (B) Quantitative distribution of the subcellular expression of PER2-GFP in NG108-15 cells. Cells were
transfected with PER2-GFP together with either empty expression plasmid, expression vector for HA-I-1*, or expression vector coding for CRY1. Cells
were assessed for predominantly nuclear, nuclear and cytoplasmic, or predominantly cytoplasmic PER2-GFP expression. Relative distribution was
determined blinded in three independent experiments. The distribution was evaluated in at least 80 GFP-positive cells for each experiment. Data are
represented as mean + SD.
doi:10.1371/journal.pone.0021325.g005
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system.
The signaling pathways mediating light input to the clock
involve phospho-CREB induced Per1 and Per2 expression in the
SCN [14,15]. Our data indicate that PP1 does not significantly
affect the immediate early signaling cascades in the SCN that
ultimately lead to Per gene induction. Per1 and Per2 induction after
light pulses at CT14 or CT22 was similar in control and I-1* mice
(Figure S3). Hence, PP1 may not influence resetting of the clock
via CRE-mediated mechanisms inducing Per gene expression in
the SCN. Instead, PP1 may influence resetting of the molecular
oscillator in the SCN by acting on the phosphorylation status of
the PER proteins. Similarly, PKC has been shown to influence
phase shifting properties of the circadian clock by affecting stability
and subcellular distribution of PER2 in response to light input
[23]. In addition to the function of PP1 in the resetting
mechanisms of the SCN, this phosphatase appears also to be
involved in retinal transmission of light to the SCN specifically at
early subjective night [52].
Altogether, our experiments suggest that PP1 is a post-
translational regulator of the mammalian circadian clock in vivo.
This phosphatase modulates the period of the circadian oscillator
and serves as a negative regulator in the light-induced resetting
mechanisms in the SCN. We hypothesize that PP1 fulfills these
functions (at least in part) by influencing the dynamics of PER2
nuclear accumulation.
Materials and Methods
Plasmids
The synthetic open reading frame (ORF) coding for constitu-
tively active Inhibitor 1 (I-1*; [37]) and the coding region for the
fragment of Nuclear Inhibitor of PP1 (NIPP1*; [43]) were cloned
in frame into HA-pSCT1 (expressing the protein with a double N-
terminal HA-tag). PER2-EGFP and pSTC-CRY1 expression
vectors are described [53]. The ORF coding for a N-terminally
truncated form of beta-Catenin was cloned into pEGFPC3 and
then subcloned into the pSTC expression vector.
Virus production
RNAi constructs targeting PP1 catalytic subunits (PPP1CA/
CB/CC) and non-silencing RNAi as control were purchased from
Open Biosystems. The corresponding oligo-IDs are indicated in
Table S1. For lentivirus production HEK293T cells (Thermo
Scientific #HCL4517) were seeded in T25 flasks and transfected
with 2.5 mg psPAX, 1.5 mg pMD2G and 3.5 mg of the respective
lentiviral expression plasmid (RNAi constructs) using the
CalPhos
TM Mammalian Transfection Kit (BD-Biosciences) accord-
ing to the manufacturer’s protocol.
Virus-containing supernatants were filtered and U-2 OS
(human, American Type Culture Collection [ATCC] # HTB-
96) reporter cells stably expressing firefly luciferase from a 0.9-kb
Bmal1 promoter fragment were transduced with 1 ml of virus
filtrate plus 8 ng/mL protamine sulfate in 35 mm dishes. After 1 d,
medium was exchanged to puromycin-containing (10 mg/mL)
medium for selection.
Bioluminescence recording of transduced U-2 OS cells
3 days after transduction reporter cells were synchronized with
dexamethasone (1 mM) for 30 min. After washing with 16PBS,
cells were cultured in phenol-red-free DMEM medium containing
10% fetal calf serum, antibiotics, and 250 mM D-luciferin
(Biothema). Light emission was recorded at 37uC in a LumiCycle
photomultiplier advice (Actimetrics) for 4–6 d. Raw data were
detrended by dividing the 24-h-running average. Periods were
estimated by fitting the cosine wave function as described [24].
Determination of knock-down efficiency by Quantitative
PCR
For testing knockdown efficiencies of the respective RNAi
constructs, cells were harvested immediately after bioluminescence
recording. Total RNA was prepared using RNeasy Mini Kit
(Qiagen, Hilden) and then reversely transcribed to cDNA using
Superscript RNase H- (Invitrogen). Quantitative PCR was
performed with SYBRGreen fluorescence assays using human
QuantiTect Primer Assays (Qiagen) and analyzed by ABI PRISM
7000 detection system (Applied Biosystems). The transcript levels
for each clock gene were normalized to hGapdh and evaluated
according to the 2-deltadeltaCt method [54].
Real-time bioluminescence monitoring of transfected
NIH 3T3 cells
Proliferating NIH 3T3 mouse fibroblasts [62] cultured on
35-mm dishes in DMEM High Glucose (Sigma-Aldrich) supple-
mented with 100 U/ml penicillin/streptomycin (Amimed) and
10% fetal calf serum (Amimed) were transfected with Bmal1 ext.
luciferase reporter vector [55], pCMV SEAP for normalization, and
the indicated expression vectors using linear polyethylenimine
(Polysciences Europe) according to the manufacturer’s instruc-
tions. 48 hours after transfection, cells were synchronized by
addition of DMEM containing 100 nM dexamethasone [56].
After 20 min, the medium was changed to phenol red-free
DMEM supplemented with 5% fetal calf serum and 0.1 mM
luciferine. Bioluminescence was recorded in real-time using a
LumiCycle apparatus (Actimetrics). Differences in transfection
efficiencies between different cultures were corrected for by
normalization to the secreted alkaline phosphatase activity (SEAP
activity; Roche Applied Science) measured in a culture medium
sample taken before synchronization of the cells. Bioluminescence
recordings were analyzed with LumiCycle analysis software
(Actimetrics).
Animals
Animal care and handling was performed in accordance with
the guidelines of the Schweizer Tierschutzgesetz (TSchG, SR455)
and the declaration of Helsinki. The protocol was approved by the
state veterinarian of to the Canton of Fribourg (permit FR 11/10).
tetO-I-1* mice [38] or tetO-NIPP1* mice [43] were crossed with
mice expressing the reverse tetracycline controlled transactivator
(rtTA2) under the Ca
2+/CaM-dependent protein kinase IIalpha
(CaMKIIalpha) promoter [39] to obtain double transgenic mice. As
controls, littermates carrying no transgene or one allele of either
transgene were used. For doxycycline treatment, mice were fed
doxycycline containing normal chow at 6 mg per 1 g food for at
least 8 days. Adult male mice (3–8 months old) were used for
behavioral experiments.
Protein phosphatase assay
PP1 protein phosphatase assays were performed using whole
cell SCN extracts as previously described [43]. Tissue containing
the SCN was dissected out of a 1 mm thick coronal brain slice
using a mouse brain slicer (Zivic instruments).
Locomotor activity and circadian phenotype analysis
Mice housing and handling was performed as described [42].
Animals were tested for their circadian phenotype without
doxycycline treatment (off dox), during doxycyline treatment (on
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conditions, doxycycline-containing chow was replaced by normal
chow and animals were analyzed for circadian behavior after a
waiting period of at least 10 days. For LD – DD transitions, lights
were turned off at the end of the light phase and not turned on
again the next morning. We used the Clocklab software
(Actimetrics) for wheel running data acquisition and analysis.
Activity records are double-plotted so that each day cycle’s activity
is plotted both to the right and below that of the previous cycle.
The free-running period length was determined on 10 consecutive
days of stable free-running activity in constant darkness by
x
2-periodogram analysis. For light-induced phase shifts, we used
the Aschoff type I protocol as described [42]. Animals were kept in
constant darkness for at least 21 days before and after light
administration [15 min bright white light (400 Lux) at circadian
times (CT) CT10, CT14 and CT22]. The phase shift was
determined by fitting regression lines through at least 7
consecutive onsets of activity before the light pulse and at least 7
consecutive onsets of activity after the light pulse. The two days
following the light pulse were not considered for the evaluation of
the phase shift. The difference between the two regression lines on
the first day after the light pulse determined the phase shift.
Protein extraction and Western blot analysis
Cell nuclei from mouse brain and liver were purified with the
method described in [57]. To obtain sufficient brain material,
2 mm thick coronal brain slices containing the SCN were cut
using a mouse brain slicer (Zivic instruments). The material from
two mouse brain slices containing two SCN pairs was pooled and
homogenized for one experiment. Nuclear extracts were prepared
using the NUN procedure [58]. SDS-PAGE and immunoblot
analysis were performed according to standard protocols.
Antibodies used were rabbit PER1, PER2, BMAL1, CLOCK
[59], RNA POLII (Bethyl). Quantification was performed using
the Quantity One 1-D analysis software (Biorad). Relative PER2
abundance was calculated by defining the control PER2 level at
ZT20 of each experiment as 100% (n=2 individual experiments
with a total of 4 animals).
In situ hybridization
Animals (on dox) were exposed to a 15 min light pulse (400 lux)
at either CT14 or CT22. 45 min after the end of the light pulse
mice were sacrificed. Control animals were sacrificed without prior
light exposure. Specimen preparation,
35S-UTP labeled riboprobe
synthesis and hybridization steps were performed as described
earlier [60]. The in situ hybridization probes were for mPer1 and
mPer2 as described [61]. Quantification was performed by
densitometric analysis of autoradiograph films (Amersham Hy-
perfilm MP) using the Quantity One 1-D analysis software
(Biorad). Data from the SCN were normalized by comparison with
the signal intensities in an equal area of the lateral hypothalamus.
For each time point and genotype, 2–4 animals were used and 6
sections per SCN were analyzed. Relative mRNA abundance
values were calculated by defining the wild-type control value of
each experiment as 1.
Immunohistochemistry
Tissue fixation in 4% PFA, dehydration, embedding and
sectioning was performed as described for the in situ hybridization
[60]. Following removal of embedding medium, 7 mm sections
were rehydrated and boiled in 0.01 M Na-Citrate pH 6/ 0.05%
Tween-20 for 10 min to unmask hidden antigen epitopes. After
two washing steps in 16 PBS pH 7.4, the specimens were
incubated in 3% H2O2 to inhibit endogenous peroxidases.
Sections were blocked for 1 hour at room temperature in 10%
serum, incubated overnight with the primary antibody at 4uCi n
humidified chamber and processed for immunohistochemical
detection by using the Vectastain ABC kit (Vector laboratories)
and diaminobenzidine tetrahydrochloride (DAB) as substrate
(Sigma-Aldrich). The antibody used was rabbit antiPER2 (Alpha
Diagnostic).
Imaging and evaluation of GFP expression
NG108-15 neuroblastoma6glioma hybrid cells [63] were grown
on poly-L-lysine coated coverslips in DMEM High Glucose
(Sigma-Aldrich) supplemented with 10% FCS (Amimed) and
100 U/ml penicillin/streptomycin (Amimed) and were transfected
with constructs coding for the indicated proteins. Transfection was
performed using linear polyethylenimine (Polysciences Europe)
according to the manufacturer’s instructions. 24 hours after
transfection, cells were fixed by incubation with 4% PFA and
coverslips were mounted on glass slides. The cells expressing GFP-
tagged proteins were analyzed and assigned to three different
categories according to their predominantly nuclear, nuclear and
cytoplasmic, or predominantly cytoplasmic expression. An exam-
iner unconscious of the condition each image belonged to did the
evaluation.
Cycloheximide experiment
NG108-15 neuroblastoma6glioma hybrid cells [63] were grown
on 10-cm dishes in DMEM High Glucose (Sigma-Aldrich)
supplemented with 10% FCS (Amimed) and 100 U/ml penicil-
lin/streptomycin (Amimed) and were transfected with equal
amounts of pSCT1 Per2-V5 [55], and either empty vector, or
vectors coding for HA-I-1* and HA-NIPP1* using linear poly-
ethylenimine (Polysciences Europe) according to the manufacturer’s
instructions. After having reached confluency, cells were split on
5-cm dishes. After 48 hours, cells were treated with 25 mg/ml
cycloheximide (Sigma) for 0, 1, 2, or 4 hours. Cells were washed
twice with 16PBS and resuspended in NDB buffer [100 mM KCl,
0.2 mM EDTA, 20% Glycerol, 20 mM Hepes pH 7.6, 2 mM
DTT] and lysed with an equal volume of NUN buffer [600 mM
NaCl, 2 M Urea, 2% NP-40, 50 mM Hepes pH 7.6] supplemented
with protease and phosphatase inhibitors. Samples were analyzed
by immunoblotting. Antibodies used were anti-V5 (Sigma) and
anti-Actin (Sigma).
Statistical analysis
Significant differences were determined using Prism 4 software
(GraphPad). To assess the effect of genotype and treatment on
period length in mice, a 2-way ANOVA analysis with repeated
measures on the treatment factor was performed comparing
control and mutant animals under off, on and on/off dox
conditions. This was followed by Bonferroni post-tests comparing
genotype within each level of treatment since there is a scientific
justification not to be interested in the comparison of off dox
control and on/off mutant, for example. Additionally, data sets
were analyzed using paired t-tests. Other data were analyzed
performing either unpaired t-test (to compare two groups) or a
1-way Anova with Bonferroni post-test (to compare several
groups), as indicated in the figure legends. Values were considered
significantly different with p,0.05 (*), p,0.01 (**), or p,0.001
(***).
Supporting Information
Figure S1 Controls of knock-down experiments. (A)
Knock-down efficiency of transduced RNAi constructs in U-2
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PPP1CB, or PPP1CC) in cells transduced with the non-silencing
construct were set to 1. (B) Average period length of Bmal1 luc
oscillations in U-2 OS cells not transduced (medium) or
transduced with a construct containing scrambled RNAi (non-
silencing control) or antisense constructs against the catalytic
subunits of PP1, respectively. Period length was determined in
three independent experiments (with n=2–3 cultures). For
PPP1CB and PPP1CC two different antisense constructs were
used. *** p,0.001, * p,0.05 indicating significance (1-way
Anova). The oligo-ID’s for the corresponding antisense constructs
are indicated in table S1.
(TIF)
Figure S2 NIPP1* expression in the brain has minor
effects on the circadian free-running period length.
Average period length of control mice and NIPP1* mutants in
constant darkness under off dox, on dox and on/off dox
conditions. Data are presented as mean 6 SEM.
(TIF)
Figure S3 Light inducibility of Per1 and Per2 is similar
in control and I-1* mutant mice. (A) Induction of Per1
expression in the SCN by a 15-min light pulse applied at CT14 as
revealed by in situ hybridization. (B) Induction of Per2 expression
by a 15-min light pulse applied at CT14. (C) Induction of Per1
expression by a 15-min light pulse applied at CT22. (D) Induction
of Per2 expression by a 15-min light pulse applied at CT22. Light
treated and control animals were sacrificed at CT15 or CT23,
respectively. The left panels show representative micrographs. The
location within the SCN of each section was determined by
Hoechst dye staining (blue). The in situ hybridization signal is given
in yellow. The quantifications show means 6 SEM of normalized
optical densities. All experiments were performed with animals
under doxycycline treatment (n=2–4). Scale bar 200 mm.
(TIF)
Figure S4 PER2 expression in the SCN of control and I-
1* mutant mice. (A) Immunohistochemical analysis of PER2 in
the SCN of control and I-1* mutant mice under on dox
conditions. Animals maintained in a LD 12:12 h cycle were
sacrificed every 6 hours. Representative micrographs are shown.
The location of each section was determined by Hoechst dye
staining. Scale bar 200 mm. (B) Immunohistochemical analysis of
PER2 in the SCN at ZT2 at a higher magnification (640). The top
panels show the aPER2 staining, the middle panels the Hoechst
dye staining and the lower panels represent the merge of the two
stainings. Scale bar 20 mm. (C) Quantitative representation of
subcellular localization of PER2 in the SCN at ZT2 in control and
I-1* mutant mice. The quantification shows the percentage of cells
showing nuclear (N), nuclear and cytoplasmic (N/C) and
cytoplasmic PER2 staining. The quantification includes data from
5 SCN sections (approximately 80 nuclei/ section) for each
genotype.
(TIF)
Figure S5 HA-NIPP1* expression alters the subcellular
localization of PER2-GFP in NG108-15 cells. (A) Repre-
sentative micrographs of cells transfected with expression vectors
for PER2-GFP and HA-NIPP1*. Shown is the GFP fluorescence
(green, left panel), the Hoechst-stain fluorescence (blue, middle
panel) and the merge of the two images (right panel). (B)
Quantitative representation of the subcellular localization of
PER2-GFP expression in NG-108-15 cells. (C) Quantitative
representation of the subcellular localization of beta-Catenin-
GFP expression. NG108-15 cells were transfected with an
expression vector for beta-Catenin-GFP together with either
empty pSCT1 expression vector, pSCT1-HA-I-1*, or pSCT1-
HA-NIPP1*. GFP positive cells were scored for predominantly
nuclear, nuclear and cytoplasmic and predominantly cytoplasmic
expression. The relative distribution was determined blinded in
three independent experiments (out of 80 GFP-positive cells each).
Data are represented as mean + SD.
(TIF)
Figure S6 Cycloheximide treatment. (A) NG-108-15 cells
transiently expressing Per2-V5 either alone or together with
HA-I-1* or HA-NIPP1* were treated for up to 4 hours with
25 mg/ml cycloheximide. Samples were analyzed by immunoblot-
ting using the indicated antibodies. (B) Two individual experi-
ments were quantified using the Quantity One 1-D analysis
software (Biorad). For each time point, the amount of PER2-V5
was normalized to actin. For each experiment, the normalized
amount of PER2-V5 at time point 0 was set to 100%.
(TIF)
Table S1 Antisense constructs.
(DOC)
Table S2 Period length of control and I-1* mutant mice.
(DOC)
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